Company profile: Cardiovascular Systems
1.1 - Company Overview
Company description
- Provider of medical devices for treating peripheral and coronary vascular disease, focusing on plaque removal via orbital atherectomy systems (Diamondback 360 Peripheral and Coronary OAS, Stealth 360), as well as guide wires (ViperWire Advance, Shepherd) and support catheters (ViperCross), helping physicians address difficult disease states, including calcium.
Products and services
- Diamondback 360 Coronary Orbital Atherectomy System (OAS): An OAS-class device used in coronary procedures to remove plaque from coronary arteries, addressing difficult disease states including calcium complications
- Diamondback 360 Peripheral Orbital Atherectomy System (OAS): A peripheral OAS-class medical device used for treating peripheral arterial disease by removing plaque from blood vessels, assisting physicians with complex disease states, including calcium
- Stealth 360 Peripheral Orbital Atherectomy System (OAS): A peripheral OAS-class system engineered to treat peripheral arterial disease by facilitating plaque removal from arteries to support challenging cases and calcium-related complications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cardiovascular Systems
Verathon
HQ: United States
Website
- Description: Provider of medical devices and services, designing, manufacturing and distributing solutions for airway management and bladder volume measurement, including GlideScope video laryngoscopes, GlideScope Core airway visualization systems, GlideScope Go 2 for EMS, GlideScope Spectrum QC single-use laryngoscopes, BFlex single-use bronchoscopes, and BladderScan ultrasound devices with AI.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verathon company profile →
Omeicos
HQ: Germany
Website
- Description: Provider of first-in-class small-molecule therapeutics based on omega-3 fatty acid metabolites for the treatment and prevention of atrial fibrillation and broader indications. Offers OMT-28, a synthetic analog of 17,18-EEQ for cardiovascular inflammation and mitochondrial dysfunction; conducts the PMD-OPTION study in Primary Mitochondrial Disease; and develops a pipeline of proprietary omega-3 analogs for cardiovascular, inflammatory, and mitochondrial diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omeicos company profile →
Telerhythmics
HQ: United States
Website
- Description: Provider of a line of cardiac monitors, delivering cutting-edge technology, easy enrollment, and fast, accurate results to meet the needs of physicians and their patients, with a focus on heart health and patient well-being.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Telerhythmics company profile →
Instylla
HQ: United States
Website
- Description: Provider of next-generation liquid embolics for interventional radiology. Offers the Embrace Hydrogel Embolic System (HES), a device that embolizes hypervascular tumors and peripheral arterial bleeds by forming a soft hydrogel to fill vessel lumens during embolization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Instylla company profile →
Silver Creek Pharmaceuticals
HQ: United States
Website
- Description: Provider of protein therapeutics for cardiovascular disease and tissue repair, leveraging Smart Growth Factor technology to create growth factor fusion proteins for damaged tissues. Pipeline includes scp776, a targeted fusion protein in Phase II for acute ischemic stroke with preclinical efficacy in stroke, heart attack, and kidney injury, evaluated in the ARPEGGIO Phase II study for safety and neuroprotection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Silver Creek Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cardiovascular Systems
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cardiovascular Systems
2.2 - Growth funds investing in similar companies to Cardiovascular Systems
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cardiovascular Systems
4.2 - Public trading comparable groups for Cardiovascular Systems
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →